Cypre Inc.
- Biotech or pharma, therapeutic R&D
Cypre builds next-generation tumor organoids that decode immune and stromal response for oncology drug development.
Our immune-integrated platform combines human tumor, fibroblast, and immune cells to model complex tumor microenvironment biology – enabling high-content phenotypic screening, MOA discovery, and immune-modulated response analytics.
Validated through a partnership with Charles River Laboratories across solid tumors, we are partnering with select biopharma and platform collaborators—and are engaging investors aligned with the FDA-driven shift away from animal models toward predictive, human-relevant systems.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}